Unleashing the Potential of Tau Oligomer Inhibition™
Oligomerix® Vision
To discover novel and differentiated small molecules and biomarkers focused on tau oligomer inhibition for the disease-modifying treatment of Alzheimer’s disease and other related neurodegenerative diseases
News & Upcoming Events
February 11, 2021: Oligomerix’s presentation at the Westchester County Association All Access Healthcare: Spotlight on Westchester’s Bioscience Ecosystem
February 3, 2021: Oligomerix to Present at Upcoming Life Sciences Conferences
November 24, 2020: Finding Genius Podcast with Dr. James Moe
October 29, 2020: Oligomerix to Present at Clinical Trials on Alzheimer’s Disease Conference & Life Sciences Summit
October 8, 2020: Oligomerix Relocates Headquarters to Accommodate Growth
September 15, 2020: Oligomerix Receives $3.19 Million NIH Commercialization Readiness Pilot Grant for Alzheimer’s Disease Therapy